Oscar Health, Inc. (OSCR)
NYSE: OSCR · Real-Time Price · USD
14.09
+0.59 (4.37%)
Dec 20, 2024, 4:00 PM EST - Market closed
Oscar Health Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Oscar Health stock have an average target of 21.56, with a low estimate of 12 and a high estimate of 28. The average target predicts an increase of 53.02% from the current stock price of 14.09.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Oscar Health stock from 8 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 5 | 5 | 4 | 4 | 4 | 4 |
| Hold | 3 | 3 | 2 | 3 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 1 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 6 | 7 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Sell Initiates $12 | Sell | Initiates | $12 | -14.83% | Dec 10, 2024 |
| B of A Securities | B of A Securities | Hold → Sell Downgrades $21 → $14 | Hold → Sell | Downgrades | $21 → $14 | -4.19% | Nov 6, 2024 |
| UBS | UBS | Hold Initiates $23 | Hold | Initiates | $23 | +63.24% | Oct 7, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $28 | Buy | Reiterates | $28 | +98.72% | Sep 10, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $25 → $28 | Buy | Maintains | $25 → $28 | +98.72% | Aug 8, 2024 |
Financial Forecast
Revenue This Year
9.45B
Revenue Next Year
11.78B
from 9.45B
Increased by 24.74%
EPS This Year
0.02
from -1.22
EPS Next Year
0.77
from 0.02
Increased by 4,913.33%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 9.7B | 13.3B | 14.5B | |
| Avg | 9.4B | 11.8B | 11.9B | |
| Low | 9.0B | 10.5B | 9.9B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | 41.1% | 23.3% | |
| Avg | - | 24.7% | 1.3% | |
| Low | - | 11.0% | -16.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 0.11 | 1.54 | 1.94 | |
| Avg | 0.02 | 0.77 | 1.16 | |
| Low | -0.11 | 0.25 | 0.14 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | 9,988.2% | 153.2% | |
| Avg | - | 4,913.3% | 50.9% | |
| Low | - | 1,501.3% | -82.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.